423 related articles for article (PubMed ID: 16953186)
41. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
42. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
43. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.
Pertwee RG; Gibson TM; Stevenson LA; Ross RA; Banner WK; Saha B; Razdan RK; Martin BR
Br J Pharmacol; 2000 Apr; 129(8):1577-84. PubMed ID: 10780961
[TBL] [Abstract][Full Text] [Related]
44. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists.
Seely KA; Levi MS; Prather PL
J Pharmacol Exp Ther; 2009 Jul; 330(1):31-9. PubMed ID: 19359525
[TBL] [Abstract][Full Text] [Related]
45. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.
Guindon J; Desroches J; Beaulieu P
Br J Pharmacol; 2007 Mar; 150(6):693-701. PubMed ID: 17179944
[TBL] [Abstract][Full Text] [Related]
46. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
Savinainen JR; Kokkola T; Salo OM; Poso A; Järvinen T; Laitinen JT
Br J Pharmacol; 2005 Jul; 145(5):636-45. PubMed ID: 15852035
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
[TBL] [Abstract][Full Text] [Related]
50. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
Brizzi A; Brizzi V; Cascio MG; Corelli F; Guida F; Ligresti A; Maione S; Martinelli A; Pasquini S; Tuccinardi T; Di Marzo V
J Med Chem; 2009 Apr; 52(8):2506-14. PubMed ID: 19331413
[TBL] [Abstract][Full Text] [Related]
51. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.
Steffens M; Engler C; Zentner J; Feuerstein TJ
Br J Pharmacol; 2004 Apr; 141(7):1193-203. PubMed ID: 14993102
[TBL] [Abstract][Full Text] [Related]
52. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.
Keenan CM; Storr MA; Thakur GA; Wood JT; Wager-Miller J; Straiker A; Eno MR; Nikas SP; Bashashati M; Hu H; Mackie K; Makriyannis A; Sharkey KA
Br J Pharmacol; 2015 May; 172(9):2406-18. PubMed ID: 25572435
[TBL] [Abstract][Full Text] [Related]
53. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.
Leggett JD; Aspley S; Beckett SR; D'Antona AM; Kendall DA; Kendall DA
Br J Pharmacol; 2004 Jan; 141(2):253-62. PubMed ID: 14707029
[TBL] [Abstract][Full Text] [Related]
54. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.
You H; Gadotti VM; Petrov RR; Zamponi GW; Diaz P
Mol Pain; 2011 Nov; 7():89. PubMed ID: 22093952
[TBL] [Abstract][Full Text] [Related]
55. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
Rinaldi-Carmona M; Calandra B; Shire D; Bouaboula M; Oustric D; Barth F; Casellas P; Ferrara P; Le Fur G
J Pharmacol Exp Ther; 1996 Aug; 278(2):871-8. PubMed ID: 8768742
[TBL] [Abstract][Full Text] [Related]
56. N-(4-Methoxy-2-nitrophenyl)hexadecanamide, a palmitoylethanolamide analogue, reduces formalin-induced nociception.
Roa-Coria JE; Navarrete-Vázquez G; Fowler CJ; Flores-Murrieta FJ; Déciga-Campos M; Granados-Soto V
Life Sci; 2012 Dec; 91(25-26):1288-94. PubMed ID: 23069585
[TBL] [Abstract][Full Text] [Related]
57. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
59. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
60. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain.
Páldy E; Bereczki E; Sántha M; Wenger T; Borsodi A; Zimmer A; Benyhe S
Neurochem Int; 2008 Dec; 53(6-8):309-16. PubMed ID: 18804501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
